{"id":"W4417485603","doi":"10.1016/s2213-8587(25)00290-6","title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Lipid metabolism and disorders","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"ca_institutions":"Robarts Clinical Trials; Université de Montréal; Université Laval","funders":"Arrowhead Pharmaceuticals","keywords":"RNA interference; Clinical trial; Phase (matter); MEDLINE; Hydroxymethylglutaryl-CoA Reductase Inhibitors","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001394952,0.001549372,0.002545023,0.0003685153,0.0003043883,0.0009357245,0.0006254161,0.001939158,0.00696432],"category_scores_gemma":[0.001055401,0.0004872253,0.002396052,0.0003296152,0.0007783092,0.0009338039,0.0003358052,0.003000121,0.0009051688],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006404958,"about_ca_system_score_gemma":0.0006544038,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00126464,"about_ca_topic_score_gemma":0.00372591,"domain_scores_codex":[0.9996915,0.0001295319,0.00001953719,0.00006313409,0.00003184376,0.00006448475],"domain_scores_gemma":[0.999632,0.0001106083,0.00007033576,0.00002535761,0.00002960197,0.0001321032],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9430464,0.003857248,0.0009147734,0.001822027,0.003010313,0.0001049209,0.00007246263,0.000324146,0.007621419,0.0003686644,0.003420983,0.03543677],"study_design_scores_gemma":[0.9722559,0.0233279,0.001523686,0.00005747683,0.0009212396,0.0000483596,0.00002932898,0.0001904705,0.0002872997,0.0002130166,0.001129105,0.0000161616],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9515237,0.02901185,0.001666991,0.00328333,0.001805808,0.003631445,0.002999183,0.0003894411,0.005688193],"genre_scores_gemma":[0.9590747,0.01525764,0.003724874,0.005362653,0.0008019989,0.004797555,0.003239446,0.00007019062,0.007670924],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00696432,"threshold_uncertainty_score":0.02329797,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0406784810614475,"score_gpt":0.3483097237388609,"score_spread":0.3076312426774134,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}